Cardiac Biomarkers
Cardiovascular disease remains one of the leading causes of death and health burden in New Zealand. Recent data show there are nearly 11,000 deaths per year from cardiovascular disease, with ischaemic heart disease accounting for a large proportion of these and incidence and mortality rates higher among Māori and Pacific peoples. Heart disease affects an estimated 180,000 people in New Zealand and contributes significantly to hospital admissions, long-term disability and health system costs.
Cardiac biomarkers such as high sensitivity troponins, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and others play a central role in diagnosing acute coronary syndromes, stratifying risk for heart failure, and guiding therapy for chronic cardiovascular disease. Evidence from New Zealand research shows that including cardiac biomarker data in clinical assessment can significantly improve cardiovascular risk prediction in community populations beyond traditional risk factors.
Translyx is working to bring advanced cardiac biomarker diagnostics into clinical practice in New Zealand and Oceania that offer higher analytical sensitivity and faster turnaround times. These tools help emergency clinicians identify acute myocardial injury sooner, assist cardiology teams in risk stratification, and support primary care clinicians in early detection of heart failure or evolving cardiovascular conditions. Broader access to robust cardiac biomarker testing can help reduce diagnostic uncertainty, shorten time to appropriate care, and ultimately support better outcomes for people living with, or at risk of, heart disease across the region.